JP2024521131A5 - - Google Patents

Info

Publication number
JP2024521131A5
JP2024521131A5 JP2023572165A JP2023572165A JP2024521131A5 JP 2024521131 A5 JP2024521131 A5 JP 2024521131A5 JP 2023572165 A JP2023572165 A JP 2023572165A JP 2023572165 A JP2023572165 A JP 2023572165A JP 2024521131 A5 JP2024521131 A5 JP 2024521131A5
Authority
JP
Japan
Prior art keywords
polypeptide
antibody
human
binding
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521131A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030556 external-priority patent/WO2022251119A2/en
Publication of JP2024521131A publication Critical patent/JP2024521131A/ja
Publication of JP2024521131A5 publication Critical patent/JP2024521131A5/ja
Pending legal-status Critical Current

Links

JP2023572165A 2021-05-24 2022-05-23 操作されたポリペプチド Pending JP2024521131A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163192549P 2021-05-24 2021-05-24
US63/192,549 2021-05-24
US202163265032P 2021-12-06 2021-12-06
US63/265,032 2021-12-06
US202263266453P 2022-01-05 2022-01-05
US63/266,453 2022-01-05
PCT/US2022/030556 WO2022251119A2 (en) 2021-05-24 2022-05-23 Engineered polypeptides

Publications (2)

Publication Number Publication Date
JP2024521131A JP2024521131A (ja) 2024-05-28
JP2024521131A5 true JP2024521131A5 (cg-RX-API-DMAC7.html) 2025-07-03

Family

ID=82156443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572165A Pending JP2024521131A (ja) 2021-05-24 2022-05-23 操作されたポリペプチド

Country Status (13)

Country Link
US (1) US20250296986A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347642A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024521131A (cg-RX-API-DMAC7.html)
KR (1) KR20240035758A (cg-RX-API-DMAC7.html)
AU (1) AU2022280767A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024494A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218489A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003455A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023017754A2 (cg-RX-API-DMAC7.html)
IL (1) IL308509A (cg-RX-API-DMAC7.html)
MX (1) MX2023013859A (cg-RX-API-DMAC7.html)
TW (1) TW202306978A (cg-RX-API-DMAC7.html)
WO (1) WO2022251119A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
CA3183373A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
KR20230058434A (ko) 2020-08-26 2023-05-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 SARS-CoV-2를 표적으로 하는 항원 결합 분자
WO2023230439A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof
WO2023245078A1 (en) 2022-06-15 2023-12-21 Humabs Biomed Sa Anti-parvovirus antibodies and uses thereof
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
JP2025526405A (ja) 2022-07-27 2025-08-13 ヒューマブス・バイオメッド・ソシエテ・アノニム Rsv及びmpvパラミクソウイルスに対する広域中和抗体
WO2024182781A1 (en) 2023-03-02 2024-09-06 Vir Biotechnology, Inc. Coronavirus compositions and uses thereof
TW202446788A (zh) 2023-04-10 2024-12-01 美商維爾生物科技公司 結合多種薩貝冠狀病毒之抗體
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
EP4743488A1 (en) 2023-07-13 2026-05-20 VIR Biotechnology, Inc. Antibodies widely neutralizing against paramyxoviruses RSV and MPV

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2005028515A1 (ja) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. ヒトインスリン様成長因子に対する遺伝子組換え抗体
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
WO2010033279A2 (en) * 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
CN103261222B (zh) 2010-09-10 2017-07-28 医疗免疫有限公司 抗体衍生物
US9663581B2 (en) 2012-04-25 2017-05-30 Momenta Pharmaceuticals, Inc. Modified glycoproteins
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
US20160257761A1 (en) * 2015-03-06 2016-09-08 Macrogenics, Inc. HER2/neu-Specific Antibodies and Methods of Using Same
US11267899B2 (en) 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
US20200157192A1 (en) * 2017-05-10 2020-05-21 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
JP7351845B2 (ja) * 2018-03-23 2023-09-27 ブリストル-マイヤーズ スクイブ カンパニー Micaおよび/またはmicbに対する抗体ならびにそれらの使用
US20220298230A1 (en) * 2019-06-11 2022-09-22 The Rockefeller University Antibodies and methods for treatment of viral infections

Similar Documents

Publication Publication Date Title
JP7857273B2 (ja) Cd3および腫瘍抗原に結合するヘテロ二量体抗体
US11377477B2 (en) PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
US11505595B2 (en) TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
US12509495B2 (en) LAG-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and LAG-3 antigen binding domains
US20240294593A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties
JP7021127B2 (ja) ソマトスタチン受容体2に結合するヘテロ二量体抗体
JP7328761B2 (ja) 多価多重特異性ox40結合融合タンパク質
US11584794B2 (en) Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments
AU2016262368B2 (en) Heterodimeric antibodies that bind CD3 and tumor antigens
JP7178342B2 (ja) アゴニズム及びエフェクター機能が増強した改変抗体、及び他のFcドメイン含有分子
JP7010854B2 (ja) 二重特異性チェックポイント阻害剤抗体
US20220227867A1 (en) ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
CN119365490A (zh) 结合pd-l1、pd-l2和/或cd28的抗体
US20250043001A1 (en) Anti-cd28 compositions
US20240392025A1 (en) B-cell maturation antigen (bcma) binding domain compositions
HK40093127A (en) Heterodimeric antibodies that bind cd3 and tumor antigens
HK40065611A (en) Heterodimeric antibodies that bind cd3 and tumor antigens
EA044325B1 (ru) ГЕТЕРОДИМЕРНОЕ АНТИ-CD3xCD20 АНТИТЕЛО, ЕГО ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ